stoxline Quote Chart Rank Option Currency Glossary
PTC Therapeutics, Inc. (PTCT)
26.39  0.11 (0.42%)    12-08 16:00
Open: 26.28
High: 26.985
Volume: 785,753
Pre. Close: 26.28
Low: 25.93
Market Cap: 1,991(M)
Technical analysis
2023-12-08 4:45:33 PM
Short term     
Mid term     
Targets 6-month :  31.51 1-year :  36.81
Resists First :  26.98 Second :  31.51
Pivot price 23.31
Supports First :  21.51 Second :  18.13
MAs MA(5) :  25.71 MA(20) :  22.39
MA(100) :  29.11 MA(250) :  39.18
MACD MACD :  1.2 Signal :  0.5
%K %D K(14,3) :  93.7 D(3) :  94.4
RSI RSI(14): 71.5
52-week High :  59.84 Low :  17.53
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ PTCT ] has closed below upper band by 9.4%. Bollinger Bands are 0% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 27.02 - 27.12 27.12 - 27.23
Low: 25.66 - 25.78 25.78 - 25.91
Close: 26.19 - 26.38 26.38 - 26.57
Company Description

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Headline News

Tue, 05 Dec 2023
PTC Therapeutics (NASDAQ:PTCT) shareholders are up 17% this past week, but still in the red over the last three years - Yahoo Finance

Sat, 18 Nov 2023
Even after rising 10% this past week, PTC Therapeutics (NASDAQ:PTCT) shareholders are still down 68% over the past three years - Simply Wall St

Mon, 30 Oct 2023
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2023 Earnings Call Transcript - Yahoo Finance

Thu, 26 Oct 2023
PTC Therapeutics: Q3 Earnings Snapshot - Quartz

Thu, 19 Oct 2023
Why PTC Therapeutics Soared 15% Higher Today - The Motley Fool

Mon, 16 Oct 2023
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 75 (M)
Shares Float 56 (M)
Held by Insiders 2.6 (%)
Held by Institutions 107.8 (%)
Shares Short 8,080 (K)
Shares Short P.Month 7,020 (K)
Stock Financials
EPS -8.68
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -8.9
Profit Margin -80.5 %
Operating Margin -59.4 %
Return on Assets (ttm) -22.7 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth -9.5 %
Gross Profit (p.s.) 0.03
Sales Per Share 10.57
EBITDA (p.s.) -4.22
Qtrly Earnings Growth 0 %
Operating Cash Flow -224 (M)
Levered Free Cash Flow -146 (M)
Stock Valuations
PE Ratio -3.05
PEG Ratio 0.4
Price to Book value -2.97
Price to Sales 2.49
Price to Cash Flow -8.89
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android